13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rhinacanthin C Alleviates Amyloid- β Fibrils' Toxicity on Neurons and Attenuates Neuroinflammation Triggered by LPS, Amyloid- β, and Interferon- γ in Glial Cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neuroinflammation plays a central role in the pathophysiology of Alzheimer's disease (AD). Compounds that suppress neuroinflammation have been identified as potential therapeutic targets for AD. Rhinacanthin C (RC), a naphthoquinone ester found in Rhinacanthus nasutus Kurz (Acanthaceae), is currently proposed as an effective molecule against inflammation. However, the exact role of RC on neuroinflammation remains to be elucidated. In the present study, we investigated RC effect on modulating lipopolysaccharides (LPS), amyloid- β peptide (A β), or interferon- γ- (IFN- γ-) evoked pathological events in neurons and glia. Our findings demonstrated that RC prevented A β-induced toxicity in rat hippocampal neurons and attenuated LPS-activated nitric oxide (NO) production, inducible nitric oxide synthase (iNOS) expression, and NF- κB signaling in rat glia. Likewise, RC suppressed LPS-induced neuroinflammation by reducing NO production and iNOS, IL-1 β, CCL-2, and CCL-5 mRNA levels in rat microglia. Further studies using BV-2 microglia revealed that RC inhibited LPS-, A β-, and IFN- γ-stimulated IL-6 and TNF- α secretion. Of note, NF- κB and ERK activation was abrogated by RC in BV-2 cell response to A β or IFN- γ. Moreover, RC protected neurons from A β-stimulated microglial conditioned media-dependent toxicity. Collectively, these data highlight the beneficial effects of RC on neuroprotection and support the therapeutic implications of RC to neuroinflammation-mediated conditions.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

          Alzheimer disease is a progressive dementia with unknown etiology that affects a growing number of the aging population. Increased expression of inflammatory mediators in postmortem brains of people with Alzheimer disease has been reported, and epidemiological studies link the use of anti-inflammatory drugs with reduced risk for the disorder. On the initial basis of this kind of evidence, inflammation has been proposed as a possible cause or driving force of Alzheimer disease. If true, this could have important implications for the development of new treatments. Alternatively, inflammation could simply be a byproduct of the disease process and may not substantially alter its course. Or components of the inflammatory response might even be beneficial and slow the disease. To address these possibilities, we need to determine whether inflammation in Alzheimer disease is an early event, whether it is genetically linked with the disease and whether manipulation of inflammatory pathways changes the course of the pathology. Although there is still little evidence that inflammation triggers or promotes Alzheimer disease, increasing evidence from mouse models suggests that certain inflammatory mediators are potent drivers of the disease. Related factors, on the other hand, elicit beneficial responses and can reduce disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Activation of microglial cells by beta-amyloid protein and interferon-gamma.

            Alzheimer's disease is the most common cause of progressive intellectual failure. The lesions that develop, called senile plaques, are extracellular deposits principally composed of insoluble aggregates of beta-amyloid protein (A beta), infiltrated by reactive microglia and astrocytes. Although A beta, and a portion of it, the fragment 25-35 (A beta (25-35)), have been shown to exert a direct toxic effect on neurons, the role of microglia in such neuronal injury remains unclear. Here we report a synergistic effect between A beta and interferon-gamma (IFN-gamma) in triggering the production of reactive nitrogen intermediates and tumour-necrosis factor-alpha (TNF-alpha) from microglia. Furthermore, using co-culture experiments, we show that activation of microglia with IFN-gamma and A beta leads to neuronal cell injury in vitro. These findings suggest that A beta and IFN-gamma activate microglia to produce reactive nitrogen intermediates and TNF-alpha, and this may have a role in the pathogenesis of neuronal degeneration observed in ageing and Alzheimer's disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation.

              The role of microglia in neurodegeneration, toxicology and immunity is an expanding area of biomedical research requiring large numbers of animals. Use of a microglia-like cell line would accelerate many research programmes and reduce the necessity of continuous cell preparations and animal experimentation, provided that the cell line reproduces the in vivo situation or primary microglia (PM) with high fidelity. The immortalised murine microglial cell line BV-2 has been used frequently as a substitute for PM, but recently doubts were raised as to their suitability. Here, we re-evaluated strengths and potential short-comings of BV-2 cells. Their response to lipopolysaccharide was compared with the response of microglia in vitro and in vivo. Transcriptome (480 genes) and proteome analyses after stimulation with lipopolysaccharide indicated a reaction pattern of BV-2 with many similarities to that of PM, although the average upregulation of genes was less pronounced. The cells showed a normal regulation of NO production and a functional response to IFN-gamma, important parameters for appropriate interaction with T cells and neurons. BV-2 were also able to stimulate other glial cells. They triggered the translocation of NF-kappaB, and a subsequent production of IL-6 in astrocytes. Thus, BV-2 cells appear to be a valid substitute for PM in many experimental settings, incuding complex cell-cell interaction studies.
                Bookmark

                Author and article information

                Contributors
                Journal
                Oxid Med Cell Longev
                Oxid Med Cell Longev
                OMCL
                Oxidative Medicine and Cellular Longevity
                Hindawi
                1942-0900
                1942-0994
                2017
                18 October 2017
                : 2017
                : 5414297
                Affiliations
                1Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, 321 Kuang Fu 2nd Road, Hsinchu 30011, Taiwan
                2Institute of Molecular Medicine, College of Life Sciences, National Tsing Hua University, 101 Kuang Fu 2nd Road, Hsinchu 30013, Taiwan
                3ARSOA Research & Development Center, AOB Keioh Group Corp., 2961 Kobuchisawa-cho, Hokuto, Yamanashi 408-8522, Japan
                Author notes

                Academic Editor: Amira Zarrouk

                Author information
                http://orcid.org/0000-0002-5576-8135
                http://orcid.org/0000-0002-1884-3714
                http://orcid.org/0000-0001-9066-553X
                Article
                10.1155/2017/5414297
                5664341
                29181126
                b2b67378-6907-4907-8866-b7edd501213e
                Copyright © 2017 Kai-An Chuang et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 May 2017
                : 1 August 2017
                : 22 August 2017
                Funding
                Funded by: Ministry of Science and Technology of the People's Republic of China
                Award ID: 104-2311-B-007-002
                Funded by: Ministry of Economic Affairs
                Award ID: 106-EC-17-A-22-0318
                Categories
                Research Article

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article